Literature DB >> 30838647

Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

Nicola Flaum1, Richard A Hubner1, Juan W Valle1,2, Eitan Amir3, Mairéad G McNamara1,2.   

Abstract

Adjuvant chemotherapy (AC) following pancreatic carcinoma (PC) resection improves overall survival (OS). A systematic review identified 10 phase-2/3 studies investigating AC in 3644 patients looking at the influence of nodal and resection status. AC significantly improved disease free survival, OS and 5-year odds of death risk. There was greater survival benefit in patients PS 0 and with body/tail tumors. There was a nonsignificant effect in N -  /N  + patients on OS and no difference between R0/R1 patients.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  adjuvant chemotherapy; lymph nodes; meta-analysis; pancreatic cancer; resection margin; systematic review

Mesh:

Year:  2019        PMID: 30838647     DOI: 10.1002/jso.25440

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Risk Assessment of kINPen Plasma Treatment of Four Human Pancreatic Cancer Cell Lines with Respect to Metastasis.

Authors:  Sander Bekeschus; Eric Freund; Chiara Spadola; Angela Privat-Maldonado; Christine Hackbarth; Annemie Bogaerts; Anke Schmidt; Kristian Wende; Klaus-Dieter Weltmann; Thomas von Woedtke; Claus-Dieter Heidecke; Lars-Ivo Partecke; André Käding
Journal:  Cancers (Basel)       Date:  2019-08-23       Impact factor: 6.639

2.  Possible involvement of HSP70 in pancreatic cancer cell proliferation after heat exposure and impact on RFA postoperative patient prognosis.

Authors:  Hui-Bin Song
Journal:  Biochem Biophys Rep       Date:  2019-10-31

3.  Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy.

Authors:  Chen Liu; He Cheng; Kaizhou Jin; Zhiyao Fan; Yitao Gong; Yunzhen Qian; Shengming Deng; Qiuyi Huang; Quanxing Ni; Xianjun Yu; Guopei Luo
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.